SK bioscience-Sanofi: Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine

 

• The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicity data from the Phase II study.
• SK bioscience and Sanofi plan to start Phase III in H1 2024.

https://www.biospace.com/article/releases/sk-bioscience-sanofi-announce-positive-results-from-phase-ii-study-of-21-valent-pneumococcal-conjugate-vaccine-candidate/